In the treatment context, high CD49d expression (≥30% positive CLL cells) identifies cases with reduced ibrutinib-induced lymphocytosis and lower nodal responses (Figure 2). The gene discussed is ITGA4; the disease is B-cell chronic lymphocytic leukemia.